SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer

Zhang, Hong; Widegren, Emma; Wang, Dawei; Sun, Xiaoying

doi:10.1007/s13277-011-0226-x

Cited by 27 publications

(34 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether SPARCL1 plays protective role in rectal cancers awaits further confirmation. A Swedish research team reported that SPARCL1 was positively associated with well differentiation, which is consistent with our findings (19). However, their patient-based data indicated that SPARCL1 prognosticates poor survival in CRCs (19).…”

Section: Discussionsupporting

confidence: 92%

“…Previously, pilot studies showed that high SPARCL1 expression level is associated with welldifferentiated status, less metastasis, and better survival in CRCs (18). Similar results were obtained by other investigators that indicated that the expression of SPARCL1 increased with greater level of differentiation and decreased in progressing from Dukes stage B to D. However, their data showed that expression of SPARCL1 led to poor survival in CRCs (19). Therefore, the prognostic value of SPARCL1 needs to be further investigated at multiple centers with larger population.…”

Section: Introductionsupporting

confidence: 75%

See 1 more Smart Citation

Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Zhang

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is an extracellular matrix glycoprotein with malignancy-suppressing potential. The hypothesis that SPARCL1 reduces cancer invasiveness and predicts better survival in colorectal cancers (CRC) was investigated.Experimental Design: Stable SPARCL1 transfectants, RKO-SPARCL1, and corresponding vector control were constructed and implanted into nude mice to generate a mouse xenograft model of liver metastasis. Also, a retrospective outcome study was conducted on the COH set (222 CRCs) and ZJU set (412 CRCs). The protein expression level of SPARCL1 was determined by immunohistochemistry. The Kaplan-Meier and Cox analyses were used for survival analysis. The association of SPARCL1 with mesenchymal-epithelial transition (MET) was examined by reverse transcription PCR (RT-PCR) and Western blot analysis.Results: The ectopic expression of SPARCL1 significantly reduced the potential for anchorage-independent growth, migration, invasion and induced cell differentiation in RKO and SW620 cells. In mouse xenograft model, the expression of SPARCL1 significantly reduced the liver metastasis (P < 0.01). The patient-based studies revealed that the expression of SPARCL1 was related to better differentiation (P < 0.01), less lymph node involvement [OR, 0.67; 95% confidence interval (CI), 0.45-1.00], and less distant metastasis (OR, 0.38; 95% CI, 0.18-0.79). The Kaplan-Meier and Cox analysis showed that the expression of SPARCL1 was associated with better overall survival (log-rank: P < 0.01; HR, 0.57; 95% CI, 0.39-0.84). Transfection of SPARCL1 induced MET of colon cancer cells.Conclusion: SPARCL1 functions as a tumor suppressor promoting differentiation possibly via MET, which inhibits the aggressiveness of CRCs.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionsupporting

confidence: 75%

Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Zhang

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…16). The almost exclusive expression of SPARCL1 in ECs was the subject of controversy in previous studies (24,39). However, our results are strongly supported by the consistent confirmation we obtained with 3 different methods (permanent IHC, immunofluorescence IHC, and ISH) and the agreement with studies by others in humans and mouse models (11,57,58).…”

Section: Discussionsupporting

confidence: 91%

“…SPARCL1 is described as an antiadhesive protein (38) that exerts antitumorigenic activity specifically in CRC if recombinantly expressed in or added as a purified protein to RKO or SW620 cell lines (24,37). As yet in CRC tissues, SPARCL1 expression has been detected in CRC tissues, but conflicting results exist with respect to its presence in tumor cells and/or ECs, and, as such, its association with prognosis is a subject of controversy (24,39). As yet, nothing is known about the regulation or induction of SPARCL1 expression or its functional impact on vessel phenotype in human carcinomas.…”

Section: 2mentioning

confidence: 99%

Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma

Naschberger¹,

Liebl²,

Schellerer³

et al. 2016

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…Particularly, growing evidence shows that SPARCL1 often presents a reduced or absent expression pattern in a variety of human tumor tissues (Bendik et al, 1998;Nelson et al, 1998;Isler et al, 2004;Esposito et al, 2007;Zaravinos et al, 2011;Hurley et al, 2012;Li et al, 2012). However, several studies have also found that an increased expression of SPARCL1 in a few of other type of human tumors derived from liver (Lau et al, 2006), uterus (Mencalha et al, 2008), and colon and rectum (Zhang et al, 2011;Hu et al, 2012). All these conflicting findings suggest that SPARCL1 is indeed implicated in human cancer development and progression, but its expression pattern may be in a tissue-specific manner.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

Cao¹,

Kuo²,

Zhu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Secreted protein acidic and rich in cysteines-like protein 1 (SPARCL1), an extracellular matrix glycoprotein, has been implicated in the pathogenesis of several disorders including cancer. However, little is known about the expression and significance of SPARCL1 in human breast cancer. The aim of this study was to determine the expression pattern and clinicopathological significance of SPARCL1 in a Chinese breast cancer cohort. mRNA and protein expression of SPARCL1 in human breast cancer cell lines and breast cancer tissues was detected using the reverse transcription-polymerase chain reaction, real-time quantitative PCR, and Western blotting, respectively. Immunostaining of SPARCL1 in 282 Chinese breast cancer samples was examined and associations with clinicopathological parameters were analyzed. Compared to the positive expression in immortalized human breast epithelial cells, SPARCL1 was nearly absent in human breast cancer cell lines. Similarly, a significantly reduced expression of SPARCL1 was observed in human breast cancer tissues compared to that in normal breast epithelial tissues, for both mRNA and protein levels (P < 0.001). Immunohistochemical analysis showed that strong cytoplasmic immunostaining of SPARCL1 was observed in almost all normal breast samples (43/45) while moderate and strong immunostaining of SPARCL1 was only detected in 191 of 282 (67.7%) breast cancer cases. Moreover, down-regulation of SPARCL1 was significantly correlated with lymphatic metastasis (P = 0.020) and poor grade (P = 0.044). In conclusion, SPARCL1 may be involved in the breast tumorigenesis and serve as a promising target for therapy of breast cancer.

show abstract

SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer

Abstract: Background: Accumulating evidence has shown that cancers are the results of

Cited by 27 publications

References 17 publications

Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma

Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

Contact Info

Product

Resources

About